How to buy Ocugen stock | $0.316

Ocugen, Inc is a biotechnology business based in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Ocugen employs 16 staff and has a trailing 12-month revenue of around USD$42,620.

How to buy shares in Ocugen

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Ocugen. Find the stock by name or ticker symbol: OCGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ocugen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$0.316, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ocugen, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Ocugen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Ocugen share price

Use our graph to track the performance of OCGN stocks over time.

Ocugen shares at a glance

• Key figures

Information last updated 2021-01-14.

Latest market close	USD$0.316
52-week range	USD$0.185 - USD$3.5
50-day moving average	USD$1.2123
200-day moving average	USD$0.5577
Wall St. target price	USD$0.9
PE ratio	0.0762
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.8349

Buy Ocugen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Ocugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ocugen, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocugen price performance over time

Historical closes compared with the close of $0.316 from 2020-10-16

1 week (2021-01-08)	-88.25%
1 month (2020-12-16)	5.33%
3 months (2020-10-16)	0.316
6 months (2020-07-16)	51.20%

1 year (2020-01-16)	-54.63%
2 years (2019-01-16)	120.98%
3 years (2018-01-16)	2.69
5 years (2016-01-15)	2.23

Is Ocugen under- or over-valued?

Valuing Ocugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ocugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ocugen's P/E ratio

Ocugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Ocugen shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Ocugen financials

Revenue TTM	USD$42,620
Gross profit TTM	USD$0
Return on assets TTM	-38.66%
Return on equity TTM	-850.6%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$405.1 million

TTM: trailing 12 months

Shorting Ocugen shares

There are currently 5.0 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 19.7% up from 4.2 million last month.

There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.

Ocugen's "short interest ratio" (SIR)

Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 27.7 million). Ocugen's SIR currently stands at 0.18. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 180 shares are currently held short.

However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 110 shares are currently held short) or 0.1126% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 113 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.

Find out more about how you can short Ocugen stock.

Ocugen share dividends

We're not expecting Ocugen to pay a dividend over the next 12 months.

Have Ocugen's shares ever split?

Ocugen's shares were split on a 1:60 basis on 30 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.

Ocugen overview

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.

Frequently asked questions

• What percentage of Ocugen is owned by insiders or institutions?

  Currently 3.264% of Ocugen shares are held by insiders and 13.125% by institutions.

• How many people work for Ocugen?

  Latest data suggests 16 work at Ocugen.

• When does the fiscal year end for Ocugen?

  Ocugen's fiscal year ends in December.

• Where is Ocugen based?

  Ocugen's address is: 5 Great Valley Parkway, Malvern, PA, United States, 19355

• What is Ocugen's ISIN number?

  Ocugen's international securities identification number is: US67577C1053

• What is Ocugen's CUSIP number?

  Ocugen's Committee on Uniform Securities Identification Procedures number is: 43358V109